QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-reiterates-buy-on-summit-therapeutics-maintains-40-price-target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.

 barclays-maintains-underweight-on-summit-therapeutics-raises-price-target-to-16

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Underweight and raises the price target fro...

 hc-wainwright--co-maintains-buy-on-summit-therapeutics-lowers-price-target-to-40

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pri...

 citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-40

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

 whats-going-on-with-summit-therapeutics-stock-on-monday

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...

 jmp-securities-reiterates-market-outperform-on-summit-therapeutics-maintains-40-price-target

JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains ...

 retail-investors-top-stocks-with-earnings-this-week-tesla-netflix-intel-and-more

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

 summit-therapeutics-q3-adj-eps-013-inline

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This...

 summit-therapeutics-said-that-based-on-harmoni-trial-data-it-plans-to-submit-a-biologics-license-application-for-ivonescimab-plus-chemotherapy-for-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-in-q4-of-2025

Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study ResultsExpansion of Summit'...

 reported-sunday-summit-announces-ivonescimab-achieved-median-progression-free-survival-of-1114-months-compared-to-690-months-for-tislelizumab-plus-chemotherapy-in-landmark-harmoni-6-trial

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti...

 summit-therapeutics-initiates-global-phase-iii-harmoni-gi3-trial-evaluating-ivonescimab-plus-chemotherapy-in-metastatic-colorectal-cancer

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLCClinical Trial Site Activati...

 intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

 nvidia-high-fives-palantir-rocket-lab--on-this-list-of-10-bagger-legends

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION